SlideShare una empresa de Scribd logo
1 de 15
Descargar para leer sin conexión
Mergers & Acquisitions
Pharma Industry
19-06-2013 1M&A in the Pharma Industry_ Group7
19-06-2013 2M&A in the Pharma Industry_ Group7
Problems faced by the Indian Pharmaceutical Companies :-
•Rising power costs, pricing curbs and other policy uncertainties.
•Government wants to increase its ambit from 74 bulk drugs to over 640, thus
reducing the revenue generating medicines.
•Political stamp on the price, with United Progressive
•Alliance(UPA) planning free medicines for the poor.
•Fragmented and competitive market with difficulty in
gaining market share.
The Scenario:-
 High expectations by Indian promoters because of rising interest of MNC’s in local
pharmaceutical companies. (Mylan bought Agila by paying eight times its last year's
revenue)
Foreign proposals to invest in Indian drug makers are stuck at the government because
of the argument that MNC’s are buying local companies only to stifle competition.(100%
FDI allowed).
 Guidelines being formed to enable the Competition Commission to take certain drug
related decisions in case of the foreign investments in Indian pharmaceutical companies.
In the past, acquisitions in the Indian pharmaceutical market were driven by different
reasons. E.g. In Ranbaxy's case, the star attraction was the rights it had bagged from
USFDA to launch the generic version of Lipitor, the world's largest-selling medicine.
3M&A in the Pharma Industry_ Group719-06-2013
MULTINATIONAL PHARMA COMPANIES
•To gain access to the pipeline of generic
drugs being developed by small and mid-
sized Indian companies in order to leverage
cost-effective R&D and low-cost
manufacturing having similar value.
•Patented foreign companies going off
patent in order to increase the number of
blockbuster drugs going off-patent & focus
on generics adoption globally.
•The manufacturing cost
is about 30% cheaper in
India than in the US.
•The cost of developing a
generic drug in India is
about half of that in the
US.
INDIAN PHARMA COMPANIES
•Indian Pharmaceutical Co’s lack marketing
their setup in local geographies. Tie ups with
MNC’s help Indian companies to develop
expertise outside India.
•The foreign companies help the Indian
companies create a base for infrastructure as
they are already well established in their
respective countries.
•MNC’s help commercializing the products of
Indian companies through well established
distributors and retail chains.
4M&A in the Pharma Industry_ Group719-06-2013
Q1. Explain the trends of M&A activities in global pharmaceutical
industry since last 3 years?
Q2. Why do you think inorganic strategies are sometimes
irreplaceable for industries like pharmaceutical?
Q3. What is the M&A trend going forward in context with the
pharmaceutical companies?
Q4. What are the other popular inorganic growth strategies adopted
by pharmaceutical companies?
5M&A in the Pharma Industry_ Group719-06-2013
•The pharmaceutical sector is currently battling with declining pipelines, patent
expirations and a clampdown on healthcare spending. As their troubles grow, the
sectors are being forced to increasingly engage in mergers and acquisitions (M&A)
activity.
•Three blockbuster deals happened in 2009. Pfizer acquired Wyeth for $68Bn, Merck
acquired Schering-Plough for $41B, and Roche acquired Gen0entech for $46B.
•In last 3 years, the pharmaceuticals and biotechnology sectors witnessed increased
M&A activity, including some big-ticket acquisitions of 72 deals worth $6bn. This
has been possible largely because the sectors have the necessary internal resources
and credit lines to finance such deals. Megamergers, which had been absent from
the sectors since 2004, made a dramatic comeback in 2009.
•The global pharmaceuticals and biotechnology sectors saw only a 1.7 percent
increase in the total number of deals. However, the total disclosed value of deals
increased by a staggering 185 percent, to US$226.2 billion. Due to the three
megamergers, valued at US$155.9 billion, the average size of the deals increased
drastically.
M&A in the Pharma Industry_ Group719-06-2013
In the period from June 08 to May 09 the pharmaceuticals sector witnessed
increased M&A activity, including some big-ticket acquisitions, compared with the
period from June 07 to May 08 . This has been possible largely because the sectors
have the necessary internal resources and credit lines to finance such deals
19-06-2013 M&A in the Pharma Industry_ Group7 7
•The total value of M&A deals targeting companies in Central Asia/Asia-Pacific
decreased by 43.8 percent to US$8.8 billion. This significant drop was due to decreased
activity in Japan, where the value of acquisitions fell from US$7.7 billion to a mere
US$87.1 million.
•However the global pharmaceuticals sector’s interest in China and India continued to
grow. These countries accounted for 146 and 38 deals, respectively, out of the 305 deals
within the region.
•India emerged as the top target country in terms of deal value, as a result of the Daiichi
Sankyo’s US$4.6 billion acquisition of Indian generics firm Ranbaxy Laboratories.
•With two large megamergers in the pharmaceuticals sector, pharmaceutical companies
accounted for more than 91 percent of the total deal value in the current review period.
•The deal value of acquisitions by pharmaceutical companies increased by 410.9 percent
8M&A in the Pharma Industry_ Group719-06-2013
•Opportunity for cost cutting earnings boost :–
Drug companies “create value” by M&As and fire a lot of people. While some costs
are unavoidable, others are duplicative. With the lower number of approvals,
especially for large-market, general practitioner drugs, the large selling organizations
have capacity.
•Developed market companies:-
The developed market companies deployed M&A to bolster their product portfolio
and expand their product offerings to customers in their existing markets of focus.
For example, Shire Pharmaceuticals(Irelands) maintained their focus on the United
States and Europe, respectively.
•Focus on biologics:-
Biotech drugs are not subject to the same risks of generic drugs as regular small
molecule drugs, so their commercial life tends to be longer. Drug companies are
looking to monoclonal antibodies not just because of their advanced science, but
because they can get paid for the innovation.
9M&A in the Pharma Industry_ Group719-06-2013
•Buying a sales force:-
Companies try & partner away their drugs to different territories in order to
capture more of the value chain – or own more of the distribution. If a company
has a hot new product soon to be approved in the US then an established sales
force helps the company to commercialize it’s product more easily due to
enhanced marketing power
•Economies of Scale :-
Horizontal mergers between equals often do not result in efficiencies and
savings in the pharmaceutical sector. While activities such as commercialization
and distribution are often scalable, R&D efficiency often suffers during a
horizontal merger of two large pharmaceutical companies. E.g. Pfizer's
acquisition of Warner Lambert and the Glaxo Wellcome and SmithKline
Beecham’s merger.
•Emerging market companies:-
Companies based in emerging markets see M&A as a way to gain access to
developed markets, which offer stable operating environments, relatively higher
price points for drugs, and high growth rates in the specialty and generics
segments. Thus helping the companies to get a shift from a relatively small,
highly fragmented domestic market to the developed one.
10M&A in the Pharma Industry_ Group719-06-2013
1. Establishment of new strategic alliances and joint ventures:-
R&D process for each drug take years and requires significant investments,
and the outcome of these investments of time and financial resources
remains unclear until the final approval of the drug. Hence pharmaceutical
companies are constantly looking for synergies that they can get from
cooperation with their competitors.
2. Several global pharmaceutical MNCs have entered into licensing
arrangements with Indian companies:-
In order to be able to dip into a ready basket of generic products, these deals
are likely to accelerate the launch of products in various generic markets
while offering the MNCs the advantage of cost effective manufacturing
3. Most of the pharmaceutical MNCs have outsourced significant portion of
manufacturing to verified third party vendors:-
They act as marketing and sales organization resulting in less capital
intensive nature of operations. The outsourcing of manufacturing to
multiple third party vendors leads to better inventory management and
consequently lower working capital engagement.
M&A in the Pharma Industry_ Group719-06-2013
4. Bio-Pharma Convergence:-
Biopharmaceuticals are projected as potential drugs curing many diseases. Many
researches have proved that chemistry based medical innovations need to be
replaced by advances in biopharmaceutical research that will boost the growth
of revenues and profits in the years to come.
5. Contract Manufacturing
New start-up companies are increasingly getting international exposure through
the contract manufacturing (of patented drugs, custom synthesis and scale-ups,
specialized generics and old molecules) route. It is estimated that about 50% of
global bulk drugs / API manufacturing and around 15% of formulations
manufacturing are outsourced to low cost destinations.
6. Co-Marketing Alliances
Another growth strategy adopted by Indian firms is entering into co-marketing
alliances with foreign firms to market their products. Co-marketing alliances are
taking place not only between Indian and foreign producers, but also amongst
Indian producers. Such alliances are proven to be beneficial to both the parties.
M&A in the Pharma Industry_ Group719-06-2013
•The megamergers of 2009 have put pressure on other large pharmaceutical and
biotechnology companies. The likely candidates for the next wave of
consolidation are Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson
and Sanofi-Aventis.
•However, executives of several companies have indicated they will not join the
megamerger bandwagon, and will instead rely on their own research and
development (R&D) or enter into smaller partnerships or M&A deals.
•It is still not clear whether the sectors are heading towards more megamergers
or whether they will move towards smaller strategic acquisitions. Deals in the
biotechnology sector could increase further as small and mid-size biotechnology
companies become increasingly willing to enter into deals at value prices. Large
pharmaceutical and biotechnology companies are scouting around for deals at
much lower valuations, and the current trend of M&A in generics is one to watch
for in the future.
M&A in the Pharma Industry_ Group719-06-2013
•Executives from the global pharmaceutical industry expect to see
increased levels of consolidation, with 61% of respondents
anticipating either a significant increase or an increase in M&A
activity in 2013.
• The need for new product pipelines, new product acquisition,
patent expiries, cost containment, and credit availability are
identified as the key drivers for increase in M&A activities in the
global pharmaceutical industry.
•Larger companies have cash piled in their accounts books, while
their product line is limited to few market leading products. These
companies find it as an opportunity to acquire and leverage on
promising portfolios from smaller organizations.
14M&A in the Pharma Industry_ Group719-06-2013
19-06-2013 M&A in the Pharma Industry_ Group7 15
MADE BY:
1. Utkarsh Garg (121)
2. Sangam Lalsivaraju (138)
3. Sugandha Arora (140)
4. Dhruv Mahajan (141)
5. Nitish Dubey (177)

Más contenido relacionado

La actualidad más candente

Eli Lilly Global Strategy
Eli Lilly Global StrategyEli Lilly Global Strategy
Eli Lilly Global Strategyguest90d5a
 
Competitive advantage and strategy formulation process
Competitive advantage and strategy formulation processCompetitive advantage and strategy formulation process
Competitive advantage and strategy formulation processvitusmaren
 
Strategic management - An Outlook on Growth strategy
Strategic management - An Outlook on Growth strategyStrategic management - An Outlook on Growth strategy
Strategic management - An Outlook on Growth strategyNeha Kalal
 
Pharma industry 1-4_9_29_50
Pharma industry 1-4_9_29_50Pharma industry 1-4_9_29_50
Pharma industry 1-4_9_29_50domsr
 
Pan (Alkem) Brand Dissertition Presentation
Pan (Alkem) Brand Dissertition PresentationPan (Alkem) Brand Dissertition Presentation
Pan (Alkem) Brand Dissertition PresentationDhaval Vaghela
 
Medical Affairs
Medical AffairsMedical Affairs
Medical Affairsmbielick
 
MENA pharmaceutical review, strategies and outlook pptx
MENA pharmaceutical review, strategies and outlook pptxMENA pharmaceutical review, strategies and outlook pptx
MENA pharmaceutical review, strategies and outlook pptxWesam Nehad
 
Sun Pharma - Ranbaxy Merger Presentation
Sun Pharma - Ranbaxy Merger PresentationSun Pharma - Ranbaxy Merger Presentation
Sun Pharma - Ranbaxy Merger PresentationDeepak Shenoy
 
OTC Drug Market - Future Growth Driver for IPM
OTC Drug Market - Future Growth Driver for IPMOTC Drug Market - Future Growth Driver for IPM
OTC Drug Market - Future Growth Driver for IPMShubhankar Mazumdar
 
Business Report on Pfizer
Business Report on PfizerBusiness Report on Pfizer
Business Report on PfizerAileen Marshall
 
indian Pharmaceutical industry export import overview
indian Pharmaceutical industry export import overviewindian Pharmaceutical industry export import overview
indian Pharmaceutical industry export import overviewbipindapin
 
Strategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical IndustryStrategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical IndustryEngr. Carlo Senica, MBA, CPSM
 

La actualidad más candente (20)

Eli Lilly Global Strategy
Eli Lilly Global StrategyEli Lilly Global Strategy
Eli Lilly Global Strategy
 
Pfizer case study
Pfizer case studyPfizer case study
Pfizer case study
 
Competitive advantage and strategy formulation process
Competitive advantage and strategy formulation processCompetitive advantage and strategy formulation process
Competitive advantage and strategy formulation process
 
Pharma Patenting
Pharma PatentingPharma Patenting
Pharma Patenting
 
Strategic management - An Outlook on Growth strategy
Strategic management - An Outlook on Growth strategyStrategic management - An Outlook on Growth strategy
Strategic management - An Outlook on Growth strategy
 
Pharma industry 1-4_9_29_50
Pharma industry 1-4_9_29_50Pharma industry 1-4_9_29_50
Pharma industry 1-4_9_29_50
 
Esomeprazole plan
Esomeprazole planEsomeprazole plan
Esomeprazole plan
 
Pfizer
PfizerPfizer
Pfizer
 
Pan (Alkem) Brand Dissertition Presentation
Pan (Alkem) Brand Dissertition PresentationPan (Alkem) Brand Dissertition Presentation
Pan (Alkem) Brand Dissertition Presentation
 
Medical Affairs
Medical AffairsMedical Affairs
Medical Affairs
 
Cipla final
Cipla finalCipla final
Cipla final
 
Pfizer Inc
Pfizer IncPfizer Inc
Pfizer Inc
 
MENA pharmaceutical review, strategies and outlook pptx
MENA pharmaceutical review, strategies and outlook pptxMENA pharmaceutical review, strategies and outlook pptx
MENA pharmaceutical review, strategies and outlook pptx
 
Sun pharma
Sun pharmaSun pharma
Sun pharma
 
Sun Pharma - Ranbaxy Merger Presentation
Sun Pharma - Ranbaxy Merger PresentationSun Pharma - Ranbaxy Merger Presentation
Sun Pharma - Ranbaxy Merger Presentation
 
Abbott
AbbottAbbott
Abbott
 
OTC Drug Market - Future Growth Driver for IPM
OTC Drug Market - Future Growth Driver for IPMOTC Drug Market - Future Growth Driver for IPM
OTC Drug Market - Future Growth Driver for IPM
 
Business Report on Pfizer
Business Report on PfizerBusiness Report on Pfizer
Business Report on Pfizer
 
indian Pharmaceutical industry export import overview
indian Pharmaceutical industry export import overviewindian Pharmaceutical industry export import overview
indian Pharmaceutical industry export import overview
 
Strategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical IndustryStrategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical Industry
 

Destacado

Dabur presentation
Dabur presentationDabur presentation
Dabur presentationPankaj Baid
 
Annual Results 2016
Annual Results 2016Annual Results 2016
Annual Results 2016Sanofi
 
Merger,Acquisition&Takeovers
Merger,Acquisition&TakeoversMerger,Acquisition&Takeovers
Merger,Acquisition&Takeoversamansingh09
 
Case2 bio health_s3_group4
Case2 bio health_s3_group4Case2 bio health_s3_group4
Case2 bio health_s3_group4Arjun Choudhry
 
BRAND REVITALIZATION & REINFORCEMENT STRATEGY BY DABUR INDIA LTD.
BRAND REVITALIZATION & REINFORCEMENT STRATEGY BY DABUR INDIA LTD.BRAND REVITALIZATION & REINFORCEMENT STRATEGY BY DABUR INDIA LTD.
BRAND REVITALIZATION & REINFORCEMENT STRATEGY BY DABUR INDIA LTD.Ankit Akash
 
Project Report On M & A of Ranbaxy ltd. And Daiichi sankyo
Project Report On M & A of Ranbaxy ltd. And Daiichi sankyoProject Report On M & A of Ranbaxy ltd. And Daiichi sankyo
Project Report On M & A of Ranbaxy ltd. And Daiichi sankyoNikita Agarwal
 
Study On Pharmaceuticals Companies
Study On Pharmaceuticals CompaniesStudy On Pharmaceuticals Companies
Study On Pharmaceuticals CompaniesVarsha Chauhan
 
Ranbaxy daichii acquisition final presentation
Ranbaxy daichii acquisition   final presentationRanbaxy daichii acquisition   final presentation
Ranbaxy daichii acquisition final presentationAshutosh Mantry
 
Introduction to pharma industry
Introduction to pharma industryIntroduction to pharma industry
Introduction to pharma industryGirish Swami
 
Case of Daiichi Sankyo takeover of Ranbaxy
Case of Daiichi Sankyo takeover of RanbaxyCase of Daiichi Sankyo takeover of Ranbaxy
Case of Daiichi Sankyo takeover of RanbaxyAdityakapoors
 
Pharmaceutical Industry Overview
Pharmaceutical Industry OverviewPharmaceutical Industry Overview
Pharmaceutical Industry OverviewDemetris Iacovides
 
Cipla is a leading pharmaceutical company in india with a strong and profitab...
Cipla is a leading pharmaceutical company in india with a strong and profitab...Cipla is a leading pharmaceutical company in india with a strong and profitab...
Cipla is a leading pharmaceutical company in india with a strong and profitab...Mayank Gupt
 
Ppt on m&a final ppt
Ppt on m&a final pptPpt on m&a final ppt
Ppt on m&a final pptdarshanudeshi
 

Destacado (20)

Dabur presentation
Dabur presentationDabur presentation
Dabur presentation
 
M&A in Pharma
M&A in PharmaM&A in Pharma
M&A in Pharma
 
Annual Results 2016
Annual Results 2016Annual Results 2016
Annual Results 2016
 
Merger,Acquisition&Takeovers
Merger,Acquisition&TakeoversMerger,Acquisition&Takeovers
Merger,Acquisition&Takeovers
 
Case2 bio health_s3_group4
Case2 bio health_s3_group4Case2 bio health_s3_group4
Case2 bio health_s3_group4
 
Mergers and Acquisitions (2)
Mergers and Acquisitions (2)Mergers and Acquisitions (2)
Mergers and Acquisitions (2)
 
BRAND REVITALIZATION & REINFORCEMENT STRATEGY BY DABUR INDIA LTD.
BRAND REVITALIZATION & REINFORCEMENT STRATEGY BY DABUR INDIA LTD.BRAND REVITALIZATION & REINFORCEMENT STRATEGY BY DABUR INDIA LTD.
BRAND REVITALIZATION & REINFORCEMENT STRATEGY BY DABUR INDIA LTD.
 
dabur hajmola
dabur hajmoladabur hajmola
dabur hajmola
 
Project Report On M & A of Ranbaxy ltd. And Daiichi sankyo
Project Report On M & A of Ranbaxy ltd. And Daiichi sankyoProject Report On M & A of Ranbaxy ltd. And Daiichi sankyo
Project Report On M & A of Ranbaxy ltd. And Daiichi sankyo
 
Sunpharma present13
Sunpharma present13Sunpharma present13
Sunpharma present13
 
Study On Pharmaceuticals Companies
Study On Pharmaceuticals CompaniesStudy On Pharmaceuticals Companies
Study On Pharmaceuticals Companies
 
Ranbaxy daichii acquisition final presentation
Ranbaxy daichii acquisition   final presentationRanbaxy daichii acquisition   final presentation
Ranbaxy daichii acquisition final presentation
 
Introduction to pharma industry
Introduction to pharma industryIntroduction to pharma industry
Introduction to pharma industry
 
Case of Daiichi Sankyo takeover of Ranbaxy
Case of Daiichi Sankyo takeover of RanbaxyCase of Daiichi Sankyo takeover of Ranbaxy
Case of Daiichi Sankyo takeover of Ranbaxy
 
Pharmaceutical Industry Overview
Pharmaceutical Industry OverviewPharmaceutical Industry Overview
Pharmaceutical Industry Overview
 
Cipla is a leading pharmaceutical company in india with a strong and profitab...
Cipla is a leading pharmaceutical company in india with a strong and profitab...Cipla is a leading pharmaceutical company in india with a strong and profitab...
Cipla is a leading pharmaceutical company in india with a strong and profitab...
 
Pharmaceutical Industry: The Challenges and the Opportunities
Pharmaceutical Industry: The Challenges and the OpportunitiesPharmaceutical Industry: The Challenges and the Opportunities
Pharmaceutical Industry: The Challenges and the Opportunities
 
Asset Allocation
Asset AllocationAsset Allocation
Asset Allocation
 
Ppt on m&a final ppt
Ppt on m&a final pptPpt on m&a final ppt
Ppt on m&a final ppt
 
Merger and Acquistion
Merger and AcquistionMerger and Acquistion
Merger and Acquistion
 

Similar a Mergers & acquisitions pharma industry

Implications for indian_pharmaceuticals
Implications for indian_pharmaceuticalsImplications for indian_pharmaceuticals
Implications for indian_pharmaceuticalsAkshay Bawa
 
A review of marketing
A review of marketingA review of marketing
A review of marketingNilesh Shah
 
A review of marketing
A review of marketingA review of marketing
A review of marketingNilesh Shah
 
A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]WriteKraft Dissertations
 
A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]WriteKraft Dissertations
 
Merck Paper Securities and Protfolio Analysis
Merck Paper Securities and Protfolio AnalysisMerck Paper Securities and Protfolio Analysis
Merck Paper Securities and Protfolio AnalysisJason Sandoy
 
Supply chain in pharma sector
Supply chain in pharma sectorSupply chain in pharma sector
Supply chain in pharma sectorPiyush Virmani
 
The future of the pharma industry 11.07
The future of the pharma industry 11.07The future of the pharma industry 11.07
The future of the pharma industry 11.07Maria Zaritskaya
 
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth Plan
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth PlanWharton Undergraduate Healthcare Conference- Merck Revenue Growth Plan
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth PlanKazim Ali
 
Team Pique UHC Case Comp Slide Deck
Team Pique UHC Case Comp Slide DeckTeam Pique UHC Case Comp Slide Deck
Team Pique UHC Case Comp Slide DeckAnukriti Kurria
 
Merck Revenue Growth Plan - Wharton Undergraduate Healthcare Conference
Merck Revenue Growth Plan - Wharton Undergraduate Healthcare ConferenceMerck Revenue Growth Plan - Wharton Undergraduate Healthcare Conference
Merck Revenue Growth Plan - Wharton Undergraduate Healthcare ConferenceKishan Soni
 
Case Study Analysis on GlaxoSmithkline
Case Study Analysis on GlaxoSmithklineCase Study Analysis on GlaxoSmithkline
Case Study Analysis on GlaxoSmithklineAanchal Saxena
 

Similar a Mergers & acquisitions pharma industry (20)

Implications for indian_pharmaceuticals
Implications for indian_pharmaceuticalsImplications for indian_pharmaceuticals
Implications for indian_pharmaceuticals
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
 
BEACON.Dec 2013
BEACON.Dec 2013BEACON.Dec 2013
BEACON.Dec 2013
 
A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
 
A review of marketing[www.writekraft.com]
A review of marketing[www.writekraft.com]A review of marketing[www.writekraft.com]
A review of marketing[www.writekraft.com]
 
A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]
 
Merck Paper Securities and Protfolio Analysis
Merck Paper Securities and Protfolio AnalysisMerck Paper Securities and Protfolio Analysis
Merck Paper Securities and Protfolio Analysis
 
Supply chain in pharma sector
Supply chain in pharma sectorSupply chain in pharma sector
Supply chain in pharma sector
 
Pharma business models
Pharma business modelsPharma business models
Pharma business models
 
The future of the pharma industry 11.07
The future of the pharma industry 11.07The future of the pharma industry 11.07
The future of the pharma industry 11.07
 
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth Plan
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth PlanWharton Undergraduate Healthcare Conference- Merck Revenue Growth Plan
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth Plan
 
Team Pique UHC Case Comp Slide Deck
Team Pique UHC Case Comp Slide DeckTeam Pique UHC Case Comp Slide Deck
Team Pique UHC Case Comp Slide Deck
 
Merck Revenue Growth Plan - Wharton Undergraduate Healthcare Conference
Merck Revenue Growth Plan - Wharton Undergraduate Healthcare ConferenceMerck Revenue Growth Plan - Wharton Undergraduate Healthcare Conference
Merck Revenue Growth Plan - Wharton Undergraduate Healthcare Conference
 
Mera medicare
Mera medicareMera medicare
Mera medicare
 
Pharma
PharmaPharma
Pharma
 
Case Study Analysis on GlaxoSmithkline
Case Study Analysis on GlaxoSmithklineCase Study Analysis on GlaxoSmithkline
Case Study Analysis on GlaxoSmithkline
 

Más de Lal Sivaraj

Solar panel project- project management
Solar panel project- project managementSolar panel project- project management
Solar panel project- project managementLal Sivaraj
 
Business sustainability Banco Real
Business sustainability Banco RealBusiness sustainability Banco Real
Business sustainability Banco RealLal Sivaraj
 
Business sustainability HUL limited
Business sustainability HUL limitedBusiness sustainability HUL limited
Business sustainability HUL limitedLal Sivaraj
 
Virdi transformers B2B project
Virdi transformers B2B projectVirdi transformers B2B project
Virdi transformers B2B projectLal Sivaraj
 
Conjoint analysis advance marketing research
Conjoint analysis advance marketing researchConjoint analysis advance marketing research
Conjoint analysis advance marketing researchLal Sivaraj
 
Deming prize and sona koyo
Deming prize and sona koyoDeming prize and sona koyo
Deming prize and sona koyoLal Sivaraj
 
Dabbawala tiffin supply chain management
Dabbawala tiffin supply chain managementDabbawala tiffin supply chain management
Dabbawala tiffin supply chain managementLal Sivaraj
 
Cj industries supply chain management
Cj industries supply chain managementCj industries supply chain management
Cj industries supply chain managementLal Sivaraj
 
Starbucks International economics
Starbucks International economicsStarbucks International economics
Starbucks International economicsLal Sivaraj
 
Doha round International economics
Doha round International economicsDoha round International economics
Doha round International economicsLal Sivaraj
 
Dm Air France Case
Dm Air France CaseDm Air France Case
Dm Air France CaseLal Sivaraj
 
Cip presentation , summer internship at Homestead infrastructure pvt ltd
Cip presentation , summer internship at Homestead infrastructure pvt ltdCip presentation , summer internship at Homestead infrastructure pvt ltd
Cip presentation , summer internship at Homestead infrastructure pvt ltdLal Sivaraj
 
Project on Big bazaar consumer behaviour
Project on Big bazaar consumer behaviourProject on Big bazaar consumer behaviour
Project on Big bazaar consumer behaviourLal Sivaraj
 
Ethnocentrism consumer behaviour
Ethnocentrism consumer behaviourEthnocentrism consumer behaviour
Ethnocentrism consumer behaviourLal Sivaraj
 
Brand prism of Whats app
Brand prism of Whats appBrand prism of Whats app
Brand prism of Whats appLal Sivaraj
 
Human resources at ernst&young
Human resources at ernst&youngHuman resources at ernst&young
Human resources at ernst&youngLal Sivaraj
 
Starbucks' strategy
Starbucks' strategyStarbucks' strategy
Starbucks' strategyLal Sivaraj
 
Benchmarking at xerox
Benchmarking at xeroxBenchmarking at xerox
Benchmarking at xeroxLal Sivaraj
 

Más de Lal Sivaraj (20)

Solar panel project- project management
Solar panel project- project managementSolar panel project- project management
Solar panel project- project management
 
Business sustainability Banco Real
Business sustainability Banco RealBusiness sustainability Banco Real
Business sustainability Banco Real
 
Business sustainability HUL limited
Business sustainability HUL limitedBusiness sustainability HUL limited
Business sustainability HUL limited
 
Virdi transformers B2B project
Virdi transformers B2B projectVirdi transformers B2B project
Virdi transformers B2B project
 
Conjoint analysis advance marketing research
Conjoint analysis advance marketing researchConjoint analysis advance marketing research
Conjoint analysis advance marketing research
 
Deming prize and sona koyo
Deming prize and sona koyoDeming prize and sona koyo
Deming prize and sona koyo
 
Note on quality
Note on qualityNote on quality
Note on quality
 
Dabbawala tiffin supply chain management
Dabbawala tiffin supply chain managementDabbawala tiffin supply chain management
Dabbawala tiffin supply chain management
 
Cj industries supply chain management
Cj industries supply chain managementCj industries supply chain management
Cj industries supply chain management
 
Starbucks International economics
Starbucks International economicsStarbucks International economics
Starbucks International economics
 
Doha round International economics
Doha round International economicsDoha round International economics
Doha round International economics
 
Dm Air France Case
Dm Air France CaseDm Air France Case
Dm Air France Case
 
Blog management
Blog managementBlog management
Blog management
 
Cip presentation , summer internship at Homestead infrastructure pvt ltd
Cip presentation , summer internship at Homestead infrastructure pvt ltdCip presentation , summer internship at Homestead infrastructure pvt ltd
Cip presentation , summer internship at Homestead infrastructure pvt ltd
 
Project on Big bazaar consumer behaviour
Project on Big bazaar consumer behaviourProject on Big bazaar consumer behaviour
Project on Big bazaar consumer behaviour
 
Ethnocentrism consumer behaviour
Ethnocentrism consumer behaviourEthnocentrism consumer behaviour
Ethnocentrism consumer behaviour
 
Brand prism of Whats app
Brand prism of Whats appBrand prism of Whats app
Brand prism of Whats app
 
Human resources at ernst&young
Human resources at ernst&youngHuman resources at ernst&young
Human resources at ernst&young
 
Starbucks' strategy
Starbucks' strategyStarbucks' strategy
Starbucks' strategy
 
Benchmarking at xerox
Benchmarking at xeroxBenchmarking at xerox
Benchmarking at xerox
 

Último

Upgrade Your Banking Experience with Advanced Core Banking Applications
Upgrade Your Banking Experience with Advanced Core Banking ApplicationsUpgrade Your Banking Experience with Advanced Core Banking Applications
Upgrade Your Banking Experience with Advanced Core Banking ApplicationsIntellect Design Arena Ltd
 
Intellectual Property Licensing Examples
Intellectual Property Licensing ExamplesIntellectual Property Licensing Examples
Intellectual Property Licensing Examplesamberjiles31
 
Developing Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursDeveloping Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursKaiNexus
 
Trauma Training Service for First Responders
Trauma Training Service for First RespondersTrauma Training Service for First Responders
Trauma Training Service for First RespondersBPOQe
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access
 
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...ISONIKELtd
 
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfPDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfHajeJanKamps
 
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003believeminhh
 
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...IMARC Group
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access
 
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxCracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxWorkforce Group
 
Fabric RFID Wristbands in Ireland for Events and Festivals
Fabric RFID Wristbands in Ireland for Events and FestivalsFabric RFID Wristbands in Ireland for Events and Festivals
Fabric RFID Wristbands in Ireland for Events and FestivalsWristbands Ireland
 
A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.mcshagufta46
 
Scrum Events & How to run them effectively
Scrum Events & How to run them effectivelyScrum Events & How to run them effectively
Scrum Events & How to run them effectivelyMarianna Nakou
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023Steve Rader
 
7movierulz.uk
7movierulz.uk7movierulz.uk
7movierulz.ukaroemirsr
 
Amazon ppt.pptx Amazon about the company
Amazon ppt.pptx Amazon about the companyAmazon ppt.pptx Amazon about the company
Amazon ppt.pptx Amazon about the companyfashionfound007
 
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsData skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsyasinnathani
 
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHelene Heckrotte
 

Último (20)

Upgrade Your Banking Experience with Advanced Core Banking Applications
Upgrade Your Banking Experience with Advanced Core Banking ApplicationsUpgrade Your Banking Experience with Advanced Core Banking Applications
Upgrade Your Banking Experience with Advanced Core Banking Applications
 
Intellectual Property Licensing Examples
Intellectual Property Licensing ExamplesIntellectual Property Licensing Examples
Intellectual Property Licensing Examples
 
Developing Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursDeveloping Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, Ours
 
Trauma Training Service for First Responders
Trauma Training Service for First RespondersTrauma Training Service for First Responders
Trauma Training Service for First Responders
 
WAM Corporate Presentation Mar 25 2024.pdf
WAM Corporate Presentation Mar 25 2024.pdfWAM Corporate Presentation Mar 25 2024.pdf
WAM Corporate Presentation Mar 25 2024.pdf
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
 
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
 
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfPDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
 
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
 
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
 
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxCracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
 
Fabric RFID Wristbands in Ireland for Events and Festivals
Fabric RFID Wristbands in Ireland for Events and FestivalsFabric RFID Wristbands in Ireland for Events and Festivals
Fabric RFID Wristbands in Ireland for Events and Festivals
 
A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.
 
Scrum Events & How to run them effectively
Scrum Events & How to run them effectivelyScrum Events & How to run them effectively
Scrum Events & How to run them effectively
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023
 
7movierulz.uk
7movierulz.uk7movierulz.uk
7movierulz.uk
 
Amazon ppt.pptx Amazon about the company
Amazon ppt.pptx Amazon about the companyAmazon ppt.pptx Amazon about the company
Amazon ppt.pptx Amazon about the company
 
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsData skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story points
 
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
 

Mergers & acquisitions pharma industry

  • 1. Mergers & Acquisitions Pharma Industry 19-06-2013 1M&A in the Pharma Industry_ Group7
  • 2. 19-06-2013 2M&A in the Pharma Industry_ Group7 Problems faced by the Indian Pharmaceutical Companies :- •Rising power costs, pricing curbs and other policy uncertainties. •Government wants to increase its ambit from 74 bulk drugs to over 640, thus reducing the revenue generating medicines. •Political stamp on the price, with United Progressive •Alliance(UPA) planning free medicines for the poor. •Fragmented and competitive market with difficulty in gaining market share. The Scenario:-  High expectations by Indian promoters because of rising interest of MNC’s in local pharmaceutical companies. (Mylan bought Agila by paying eight times its last year's revenue) Foreign proposals to invest in Indian drug makers are stuck at the government because of the argument that MNC’s are buying local companies only to stifle competition.(100% FDI allowed).  Guidelines being formed to enable the Competition Commission to take certain drug related decisions in case of the foreign investments in Indian pharmaceutical companies. In the past, acquisitions in the Indian pharmaceutical market were driven by different reasons. E.g. In Ranbaxy's case, the star attraction was the rights it had bagged from USFDA to launch the generic version of Lipitor, the world's largest-selling medicine.
  • 3. 3M&A in the Pharma Industry_ Group719-06-2013 MULTINATIONAL PHARMA COMPANIES •To gain access to the pipeline of generic drugs being developed by small and mid- sized Indian companies in order to leverage cost-effective R&D and low-cost manufacturing having similar value. •Patented foreign companies going off patent in order to increase the number of blockbuster drugs going off-patent & focus on generics adoption globally. •The manufacturing cost is about 30% cheaper in India than in the US. •The cost of developing a generic drug in India is about half of that in the US. INDIAN PHARMA COMPANIES •Indian Pharmaceutical Co’s lack marketing their setup in local geographies. Tie ups with MNC’s help Indian companies to develop expertise outside India. •The foreign companies help the Indian companies create a base for infrastructure as they are already well established in their respective countries. •MNC’s help commercializing the products of Indian companies through well established distributors and retail chains.
  • 4. 4M&A in the Pharma Industry_ Group719-06-2013 Q1. Explain the trends of M&A activities in global pharmaceutical industry since last 3 years? Q2. Why do you think inorganic strategies are sometimes irreplaceable for industries like pharmaceutical? Q3. What is the M&A trend going forward in context with the pharmaceutical companies? Q4. What are the other popular inorganic growth strategies adopted by pharmaceutical companies?
  • 5. 5M&A in the Pharma Industry_ Group719-06-2013 •The pharmaceutical sector is currently battling with declining pipelines, patent expirations and a clampdown on healthcare spending. As their troubles grow, the sectors are being forced to increasingly engage in mergers and acquisitions (M&A) activity. •Three blockbuster deals happened in 2009. Pfizer acquired Wyeth for $68Bn, Merck acquired Schering-Plough for $41B, and Roche acquired Gen0entech for $46B. •In last 3 years, the pharmaceuticals and biotechnology sectors witnessed increased M&A activity, including some big-ticket acquisitions of 72 deals worth $6bn. This has been possible largely because the sectors have the necessary internal resources and credit lines to finance such deals. Megamergers, which had been absent from the sectors since 2004, made a dramatic comeback in 2009. •The global pharmaceuticals and biotechnology sectors saw only a 1.7 percent increase in the total number of deals. However, the total disclosed value of deals increased by a staggering 185 percent, to US$226.2 billion. Due to the three megamergers, valued at US$155.9 billion, the average size of the deals increased drastically.
  • 6. M&A in the Pharma Industry_ Group719-06-2013 In the period from June 08 to May 09 the pharmaceuticals sector witnessed increased M&A activity, including some big-ticket acquisitions, compared with the period from June 07 to May 08 . This has been possible largely because the sectors have the necessary internal resources and credit lines to finance such deals
  • 7. 19-06-2013 M&A in the Pharma Industry_ Group7 7 •The total value of M&A deals targeting companies in Central Asia/Asia-Pacific decreased by 43.8 percent to US$8.8 billion. This significant drop was due to decreased activity in Japan, where the value of acquisitions fell from US$7.7 billion to a mere US$87.1 million. •However the global pharmaceuticals sector’s interest in China and India continued to grow. These countries accounted for 146 and 38 deals, respectively, out of the 305 deals within the region. •India emerged as the top target country in terms of deal value, as a result of the Daiichi Sankyo’s US$4.6 billion acquisition of Indian generics firm Ranbaxy Laboratories. •With two large megamergers in the pharmaceuticals sector, pharmaceutical companies accounted for more than 91 percent of the total deal value in the current review period. •The deal value of acquisitions by pharmaceutical companies increased by 410.9 percent
  • 8. 8M&A in the Pharma Industry_ Group719-06-2013 •Opportunity for cost cutting earnings boost :– Drug companies “create value” by M&As and fire a lot of people. While some costs are unavoidable, others are duplicative. With the lower number of approvals, especially for large-market, general practitioner drugs, the large selling organizations have capacity. •Developed market companies:- The developed market companies deployed M&A to bolster their product portfolio and expand their product offerings to customers in their existing markets of focus. For example, Shire Pharmaceuticals(Irelands) maintained their focus on the United States and Europe, respectively. •Focus on biologics:- Biotech drugs are not subject to the same risks of generic drugs as regular small molecule drugs, so their commercial life tends to be longer. Drug companies are looking to monoclonal antibodies not just because of their advanced science, but because they can get paid for the innovation.
  • 9. 9M&A in the Pharma Industry_ Group719-06-2013 •Buying a sales force:- Companies try & partner away their drugs to different territories in order to capture more of the value chain – or own more of the distribution. If a company has a hot new product soon to be approved in the US then an established sales force helps the company to commercialize it’s product more easily due to enhanced marketing power •Economies of Scale :- Horizontal mergers between equals often do not result in efficiencies and savings in the pharmaceutical sector. While activities such as commercialization and distribution are often scalable, R&D efficiency often suffers during a horizontal merger of two large pharmaceutical companies. E.g. Pfizer's acquisition of Warner Lambert and the Glaxo Wellcome and SmithKline Beecham’s merger. •Emerging market companies:- Companies based in emerging markets see M&A as a way to gain access to developed markets, which offer stable operating environments, relatively higher price points for drugs, and high growth rates in the specialty and generics segments. Thus helping the companies to get a shift from a relatively small, highly fragmented domestic market to the developed one.
  • 10. 10M&A in the Pharma Industry_ Group719-06-2013 1. Establishment of new strategic alliances and joint ventures:- R&D process for each drug take years and requires significant investments, and the outcome of these investments of time and financial resources remains unclear until the final approval of the drug. Hence pharmaceutical companies are constantly looking for synergies that they can get from cooperation with their competitors. 2. Several global pharmaceutical MNCs have entered into licensing arrangements with Indian companies:- In order to be able to dip into a ready basket of generic products, these deals are likely to accelerate the launch of products in various generic markets while offering the MNCs the advantage of cost effective manufacturing 3. Most of the pharmaceutical MNCs have outsourced significant portion of manufacturing to verified third party vendors:- They act as marketing and sales organization resulting in less capital intensive nature of operations. The outsourcing of manufacturing to multiple third party vendors leads to better inventory management and consequently lower working capital engagement.
  • 11. M&A in the Pharma Industry_ Group719-06-2013 4. Bio-Pharma Convergence:- Biopharmaceuticals are projected as potential drugs curing many diseases. Many researches have proved that chemistry based medical innovations need to be replaced by advances in biopharmaceutical research that will boost the growth of revenues and profits in the years to come. 5. Contract Manufacturing New start-up companies are increasingly getting international exposure through the contract manufacturing (of patented drugs, custom synthesis and scale-ups, specialized generics and old molecules) route. It is estimated that about 50% of global bulk drugs / API manufacturing and around 15% of formulations manufacturing are outsourced to low cost destinations. 6. Co-Marketing Alliances Another growth strategy adopted by Indian firms is entering into co-marketing alliances with foreign firms to market their products. Co-marketing alliances are taking place not only between Indian and foreign producers, but also amongst Indian producers. Such alliances are proven to be beneficial to both the parties.
  • 12. M&A in the Pharma Industry_ Group719-06-2013 •The megamergers of 2009 have put pressure on other large pharmaceutical and biotechnology companies. The likely candidates for the next wave of consolidation are Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson and Sanofi-Aventis. •However, executives of several companies have indicated they will not join the megamerger bandwagon, and will instead rely on their own research and development (R&D) or enter into smaller partnerships or M&A deals. •It is still not clear whether the sectors are heading towards more megamergers or whether they will move towards smaller strategic acquisitions. Deals in the biotechnology sector could increase further as small and mid-size biotechnology companies become increasingly willing to enter into deals at value prices. Large pharmaceutical and biotechnology companies are scouting around for deals at much lower valuations, and the current trend of M&A in generics is one to watch for in the future.
  • 13. M&A in the Pharma Industry_ Group719-06-2013 •Executives from the global pharmaceutical industry expect to see increased levels of consolidation, with 61% of respondents anticipating either a significant increase or an increase in M&A activity in 2013. • The need for new product pipelines, new product acquisition, patent expiries, cost containment, and credit availability are identified as the key drivers for increase in M&A activities in the global pharmaceutical industry. •Larger companies have cash piled in their accounts books, while their product line is limited to few market leading products. These companies find it as an opportunity to acquire and leverage on promising portfolios from smaller organizations.
  • 14. 14M&A in the Pharma Industry_ Group719-06-2013
  • 15. 19-06-2013 M&A in the Pharma Industry_ Group7 15 MADE BY: 1. Utkarsh Garg (121) 2. Sangam Lalsivaraju (138) 3. Sugandha Arora (140) 4. Dhruv Mahajan (141) 5. Nitish Dubey (177)